RealTime Dynamix™: Rheumatoid Arthritis EU Q1
The EU biologics market for the treatment of rheumatoid arthritis (RA) is well established with a variety of drugs and mechanisms of action for treatment. Though the backbone TNF-inhibiting biologics have dominated the space for nearly two decades the availability of biosimilars and pending introduction of several new biologics and JAK-inhibitors will alter the treatment […]
RealWorld Dynamix™: DMT New Starts in Multiple Sclerosis US 2017
The Multiple Sclerosis (MS) market has become fiercely competitive with the introduction of new disease-modifying therapies (DMTs) over the past several years and new therapies, such as Roche’s ocrelizumab, on the horizon. As physicians, patients and industry adapt to these changes, Spherix Global Insights examines the most sought after market, first line new patient starts, […]
Pre-launch Intentions for Sanofi-Regeneron’s Dupixent (dupilumab) Suggest Rapid Uptake in an Area of High Unmet Need
100% of surveyed dermatologists see a role for Dupixent in their practices with most anticipating quick adoption according to a recent independent study by Spherix Global Insight Download Report Overview March 29, 2017 – Cambridge, Massachusetts. The future treatment of atopic dermatitis got a whole lot brighter yesterday with the approval of Sanofi-Regeneron’s Dupixent, the […]
Roche Nabs FDA Approval for “Game-changing” Therapy for the Treatment of Multiple Sclerosis
The Q1 edition of RealTime Dynamix™: Multiple Sclerosis published by Spherix Global Insights finds that adoption of Ocrevus will be quick for patients with primary progressive multiple sclerosis, but uptake will be more muted in patients with relapsing forms of the disease Download Report Overview: Multiple Sclerosis Download Report Overview: DMT Switching in MS CAMBRIDGE, […]
Relypsa’s Veltassa Dodges the Competition Bullet as FDA Hands AstraZeneca a Second Complete Response Letter for Hyperkalemia Agent, ZS-9
Delay gives Relypsa time to close the nephrology-to-cardiology gap for Veltassa Download Report Overview March 20, 2017 – Cambridge, Massachusetts. Sixteen months and $2.7 billion ago, ZS Pharma’s hyperkalemia candidate (ZS-9, sodium zirconium cyclosilicate) was one of the most highly anticipated drugs in the renal market. Since being acquired by AstraZeneca, the company last week […]
The Battle for Preferred Alternative Mechanism Biologic in Crohn’s Disease Heats Up as Launch of Janssen’s Stelara Approaches the Six-Month Mark
While gastroenterologists report a strong intent to increase future prescribing, they are quite divided about whether Stelara will displace Takeda’s Entyvio as the alternate mechanism share leader, according to the latest report by Spherix Global Insights Download Report Overview March 20, 2017 – Cambridge, Massachusetts. Spherix Global Insights has released “RealTime Dynamix: Crohn’s Disease, Q1 […]
RealTime Dynamix™: Bone and Mineral US Q1
The management of hyperphosphatemia, secondary hyperparathyroidism and vitamin D deficiency are challenging conditions to manage in dialysis patients. These conditions are also highly prevalent in later-stage CKD-ND patients.Current therapeutic options have multiple limitations and are associated with poor adherence. Recent launches of iron-based, non-calcium phosphate binders have not measurably shifted the market. This monthly report […]
RealTime Dynamix™: Atopic Dermatitis US Q1
Atopic dermatitis, the most common form of eczema affecting 5 to 20% of the worldwide population, is a chronic inflammatory disease often presenting as a skin rash Moderate-to-severe AD is characterized by rashes often covering much of the body, and can include intense itching and dryness, crusting, redness, and oozing which can be debilitating. Until […]
RealTime Dynamix™: Psoriasis US Q1
The Psoriasis market continues to grow, driven by a growing treatment population and the continued uptake of biologics and advanced therapies. In particular, the IL-17 class shows rapid growth, with both Cosentyx (Novartis) and 2016 launched Taltz from Eli Lilly. Tracking the interplay of these two highly regarded treatments will be central to the 2017 […]
RealTime Dynamix™: Psoriatic Arthritis US Q1
The already highly dynamic US market for Psoriatic Arthritis (PsA) with the recent entrance of Celgene’s Otezla and Novartis’ Cosentyx is set to go up another level of complexity with Eli Lilly’s Taltz and AstraZeneca/Valeant’s brodalumab close to approval dates and line extensions being sought for Pfizer’s Xeljanz and Simponi Aria from Janssen. RealTime Dynamix: […]
